Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 32


MicroRNA-27b suppresses tumor progression by regulating ARFGEF1 and focal adhesion signaling.

Matsuyama R, Okuzaki D, Okada M, Oneyama C.

Cancer Sci. 2016 Jan;107(1):28-35. doi: 10.1111/cas.12834. Epub 2015 Nov 18.


Aberrantly expressed miR-582-3p maintains lung cancer stem cell-like traits by activating Wnt/β-catenin signalling.

Fang L, Cai J, Chen B, Wu S, Li R, Xu X, Yang Y, Guan H, Zhu X, Zhang L, Yuan J, Wu J, Li M.

Nat Commun. 2015 Oct 15;6:8640. doi: 10.1038/ncomms9640.


mLST8 Promotes mTOR-Mediated Tumor Progression.

Kakumoto K, Ikeda J, Okada M, Morii E, Oneyama C.

PLoS One. 2015 Apr 23;10(4):e0119015. doi: 10.1371/journal.pone.0119015. eCollection 2015.


MicroRNAs in apoptosis, autophagy and necroptosis.

Su Z, Yang Z, Xu Y, Chen Y, Yu Q.

Oncotarget. 2015 Apr 20;6(11):8474-90. Review.


Induced miR-99a expression represses Mtor cooperatively with miR-150 to promote regulatory T-cell differentiation.

Warth SC, Hoefig KP, Hiekel A, Schallenberg S, Jovanovic K, Klein L, Kretschmer K, Ansel KM, Heissmeyer V.

EMBO J. 2015 May 5;34(9):1195-213. doi: 10.15252/embj.201489589. Epub 2015 Feb 23.


Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer.

Bailey ST, Westerling T, Brown M.

Cancer Res. 2015 Jan 15;75(2):436-45. doi: 10.1158/0008-5472.CAN-14-1041. Epub 2014 Nov 11.


Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes.

Fish EN, Platanias LC.

Mol Cancer Res. 2014 Dec;12(12):1691-703. doi: 10.1158/1541-7786.MCR-14-0450. Epub 2014 Sep 12. Review.


MicroRNAs: novel players in cancer diagnosis and therapies.

Oom AL, Humphries BA, Yang C.

Biomed Res Int. 2014;2014:959461. doi: 10.1155/2014/959461. Epub 2014 Jul 2. Review.


MicroRNA and mRNA expression profiling in rat acute respiratory distress syndrome.

Huang C, Xiao X, Chintagari NR, Breshears M, Wang Y, Liu L.

BMC Med Genomics. 2014 Jul 28;7:46. doi: 10.1186/1755-8794-7-46.


A novel small-molecule compound diaporine A inhibits non-small cell lung cancer growth by regulating miR-99a/mTOR signaling.

Song Y, Dou H, Wang P, Zhao S, Wang T, Gong W, Zhao J, Li E, Tan R, Hou Y.

Cancer Biol Ther. 2014 Oct;15(10):1423-30. doi: 10.4161/cbt.29925. Epub 2014 Jul 21.


Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a.

Zhang EB, Kong R, Yin DD, You LH, Sun M, Han L, Xu TP, Xia R, Yang JS, De W, Chen Jf.

Oncotarget. 2014 Apr 30;5(8):2276-92.


MicroRNAs: new regulators of Toll-like receptor signalling pathways.

He X, Jing Z, Cheng G.

Biomed Res Int. 2014;2014:945169. doi: 10.1155/2014/945169. Epub 2014 Mar 20. Review.


MiR-99a antitumor activity in human breast cancer cells through targeting of mTOR expression.

Hu Y, Zhu Q, Tang L.

PLoS One. 2014 Mar 17;9(3):e92099. doi: 10.1371/journal.pone.0092099. eCollection 2014.


Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction.

Li Q, Xie J, Li R, Shi J, Sun J, Gu R, Ding L, Wang L, Xu B.

J Cell Mol Med. 2014 May;18(5):919-28. doi: 10.1111/jcmm.12242. Epub 2014 Mar 13.


Comprehensive molecular characterization of urothelial bladder carcinoma.

Cancer Genome Atlas Research Network.

Nature. 2014 Mar 20;507(7492):315-22. doi: 10.1038/nature12965. Epub 2014 Jan 29.


Reciprocal regulation of microRNA-99a and insulin-like growth factor I receptor signaling in oral squamous cell carcinoma cells.

Yen YC, Shiah SG, Chu HC, Hsu YM, Hsiao JR, Chang JY, Hung WC, Liao CT, Cheng AJ, Lu YC, Chen YW.

Mol Cancer. 2014 Jan 10;13:6. doi: 10.1186/1476-4598-13-6.


Apurinic/apyrimidinic endonuclease 1 induced upregulation of fibroblast growth factor 2 and its receptor 3 induces angiogenesis in human osteosarcoma cells.

Ren T, Qing Y, Dai N, Li M, Qian C, Yang Y, Cheng Y, Li Z, Zhang S, Zhong Z, Wang D.

Cancer Sci. 2014 Feb;105(2):186-94. doi: 10.1111/cas.12334. Epub 2014 Jan 27.


MiR-424/503-mediated Rictor upregulation promotes tumor progression.

Oneyama C, Kito Y, Asai R, Ikeda J, Yoshida T, Okuzaki D, Kokuda R, Kakumoto K, Takayama K, Inoue S, Morii E, Okada M.

PLoS One. 2013 Nov 11;8(11):e80300. doi: 10.1371/journal.pone.0080300. eCollection 2013.


Tailoring mTOR-based therapy: molecular evidence and clinical challenges.

Santulli G, Totary-Jain H.

Pharmacogenomics. 2013 Sep;14(12):1517-26. doi: 10.2217/pgs.13.143. Review.


Genome-wide association study for biomarker identification of Rapamycin and Everolimus using a lymphoblastoid cell line system.

Jiang J, Fridley BL, Feng Q, Abo RP, Brisbin A, Batzler A, Jenkins G, Long PA, Wang L.

Front Genet. 2013 Aug 30;4:166. doi: 10.3389/fgene.2013.00166. eCollection 2013.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk